These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25797890)

  • 1. Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.
    Koelzer VH; Dawson H; Andersson E; Karamitopoulou E; Masucci GV; Lugli A; Zlobec I
    Transl Res; 2015 Aug; 166(2):207-17. PubMed ID: 25797890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of tapasin correlates with diminished CD8(+) T-cell immunity and prognosis in colorectal cancer.
    Sokol L; Koelzer VH; Rau TT; Karamitopoulou E; Zlobec I; Lugli A
    J Transl Med; 2015 Aug; 13():279. PubMed ID: 26310568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.
    Dawson H; Grundmann S; Koelzer VH; Galván JA; Kirsch R; Karamitopoulou E; Lugli A; Inderbitzin D; Zlobec I
    Histopathology; 2015 Apr; 66(5):715-25. PubMed ID: 25382057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
    Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
    Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
    Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
    Koelzer VH; Huber B; Mele V; Iezzi G; Trippel M; Karamitopoulou E; Zlobec I; Lugli A
    Hum Pathol; 2015 Nov; 46(11):1573-81. PubMed ID: 26351067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.
    Frey DM; Droeser RA; Viehl CT; Zlobec I; Lugli A; Zingg U; Oertli D; Kettelhack C; Terracciano L; Tornillo L
    Int J Cancer; 2010 Jun; 126(11):2635-43. PubMed ID: 19856313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study.
    Koelzer VH; Herrmann P; Zlobec I; Karamitopoulou E; Lugli A; Stein U
    BMC Cancer; 2015 Mar; 15():160. PubMed ID: 25884643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
    Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
    Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer.
    Sideris M; Papagrigoriadis S
    Anticancer Res; 2014 May; 34(5):2061-8. PubMed ID: 24778007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer.
    Zlobec I; Lugli A; Baker K; Roth S; Minoo P; Hayashi S; Terracciano L; Jass JR
    J Pathol; 2007 Jul; 212(3):260-8. PubMed ID: 17516584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.
    Lugli A; Karamitopoulou E; Panayiotides I; Karakitsos P; Rallis G; Peros G; Iezzi G; Spagnoli G; Bihl M; Terracciano L; Zlobec I
    Br J Cancer; 2009 Oct; 101(8):1382-92. PubMed ID: 19755986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
    Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of CD8+ T-cells density in stage III colorectal cancer depends on SDF-1 expression.
    Lalos A; Tülek A; Tosti N; Mechera R; Wilhelm A; Soysal S; Daester S; Kancherla V; Weixler B; Spagnoli GC; Eppenberger-Castori S; Terracciano L; Piscuoglio S; von Flüe M; Posabella A; Droeser RA
    Sci Rep; 2021 Jan; 11(1):775. PubMed ID: 33436863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer.
    Simpson JA; Al-Attar A; Watson NF; Scholefield JH; Ilyas M; Durrant LG
    Gut; 2010 Jul; 59(7):926-33. PubMed ID: 20581241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.
    Correale P; Rotundo MS; Botta C; Del Vecchio MT; Ginanneschi C; Licchetta A; Conca R; Apollinari S; De Luca F; Tassone P; Tagliaferri P
    Clin Cancer Res; 2012 Feb; 18(3):850-7. PubMed ID: 22142823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.
    Kasajima A; Sers C; Sasano H; Jöhrens K; Stenzinger A; Noske A; Buckendahl AC; Darb-Esfahani S; Müller BM; Budczies J; Lehman A; Dietel M; Denkert C; Weichert W
    Hum Pathol; 2010 Dec; 41(12):1758-69. PubMed ID: 20869097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
    Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
    Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.